Development of new veterinary antibacterials is an important and challenging endeavor. Global recognition of antimicrobial resistance as a threat across human, animal, plant, food, and environmental sectors has increased the level of scrutiny on veterinary antibacterial use. Rigorous scientific evaluation of these products has and continues to be the underpinning of effectiveness evaluations and how hazards are identified, characterized, and ultimately used to make evidence‐based and risk‐based safety decisions. Some scientific factors commonly considered in the development of veterinary antibacterials include the pathogenesis and sequelae of the indicated disease, clinical and bacteriological improvement, dosage regimen (dose amount, route, duration, frequency), and antimicrobial‐resistance qualitative risk assessments. Key discussion areas covered are how culture and susceptibility testing help determine if antibacterial effects are primarily responsible for clinical improvement and how pharmacokinetic and pharmacodynamic data can help predict success, aid in defining an adequate dosage regimen, and help minimize resistance emergence and spread.

中文翻译：

---

开发合理使用兽用抗菌药物的方法

开发新的兽用抗菌药物是一项重要且具有挑战性的工作。全球认识到抗菌素耐药性是对人类、动物、植物、食品和环境部门的威胁，这提高了对兽用抗菌药物使用的审查水平。对这些产品进行严格的科学评估已经并将继续成为有效性评估的基础，以及如何识别、描述危害并最终用于做出基于证据和基于风险的安全决策。兽用抗菌药物开发中通常考虑的一些科学因素包括所指疾病的发病机制和后遗症、临床和细菌学改善、给药方案（剂量、途径、持续时间、频率）和抗菌素耐药性定性风险评估。